A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Exclusion Criteria

• •Cancer-Specific Exclusions:
• •Patients with NSCLC known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene
• •Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
• •Spinal cord compression not definitively treated with surgery and/or radiation, and/or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>=2 weeks prior to screening
• •History of leptomeningeal disease
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
• •Uncontrolled tumor-related pain
• •Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
• •Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome
• •General Medical Exclusions:
• •Pregnant and lactating women
• •Significant cardiovascular disease
• •Severe infections within 4 weeks prior to randomization
• •Major surgical procedure other than for diagnosis within 4 weeks prior to randomization
• •Treatment-Specific Exclusions:
• •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
• •History of autoimmune disease
• •Prior allogeneic bone marrow transplantation or solid organ transplantation
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
• •Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or active tuberculosis
• •Administration of a live, attenuated vaccine within 4 weeks prior to randomization